Bexarotene
As of the edition of 20 October 2026, Bexarotene is a small molecule: marketed, first approved in 1999 (US); acts on RXRA, RXRB and RXRG; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2016
- Kind
- Small molecule
- Brand name
- Targretin
- First approved
- 29 December 1999 (US)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- Minophagen Pharmaceutical Co., Ltd.; 3 holders in all
- Registered trials
- 37, 7 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Skin and connective tissue; Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
6 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product6 company-target rows are on route B because of Bexarotene.
See the 6 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 1 | 12 | 9 | 1 | 2 |
| Phase 2 | 17 | 11 | 0 | 3 |
| Phase 3 | 6 | 3 | 0 | 2 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 37 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Ligand Pharmaceuticals | Originator and Lead sponsor of trials | 1998 to now |
| H.A.C. Pharma | Applicant | 2001 to now |
| Bausch Health | Acquired holder and Lead sponsor of trials | 2010 to now |